Filing Flows

Filing Flows › Companies › bioAffinity Technologies › Cash flow

bioAffinity Technologies cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$3.9M in Q3 2026 · −$13.0M over twelve months

Operating cash flow−$3.9M
Capital spending−$77K
Free cash flow−$3.9M

Analysis

In Q3 2026, bioAffinity Technologies generated −$3.9M of operating cash flow and spent $77K on capital projects, leaving free cash flow of −$3.9M. That is $1.5M less than in Q3 2025 (−$2.5M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$12.9M; the largest uses were operating cash flow ($12.9M), other financing ($895K), net borrowing (+) / repaid (−) ($191K); besides operations, cash came from shares issued ($9.0M); the cash balance fell by $5.1M.

Operating cash flow was −$3.9M against net income of −$5.3M. The largest differences: accrued liabilities −$271K, receivables +$153K, stock-based pay +$139K.

Free cash flow

bioAffinity Technologies: free cash flow by quarterbioAffinity Technologies: free cash flow by quarter−$1.7MQ4 2024−$1.7MQ1 2025−$2.7MQ2 2025−$2.5MQ3 2025−$2.6MQ4 2025−$3.2MQ1 2026−$3.3MQ2 2026−$3.9MQ3 2026
Operating cash flow less capital spending.
bioAffinity Technologies: operating cash flow against capital spendingbioAffinity Technologies: operating cash flow against capital spendingOperating cash flowCapital spending−$1.7M$1Q4 2024−$1.6M$51KQ1 2025−$2.6M$13KQ2 2025−$2.5M−$4KQ3 2025−$2.6M$1Q4 2025−$3.2M$6KQ1 2026−$3.2M$90KQ2 2026−$3.9M$77KQ3 2026
Latest (Q3 2026): Operating cash flow −$3.9M, Capital spending $77K.

Capital allocation, year by year

bioAffinity Technologies: where the cash came from (up) and went (down), by fiscal yearbioAffinity Technologies: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingAcquisitionsFY2021: Operating cash flow −$2.0MFY2021: Net borrowing $3.3M$3.3MFY2021FY2022: Operating cash flow −$4.1MFY2022: Net borrowing $854KFY2022: Shares issued $6.1MFY2022: Capital spending −$220K$7.0MFY2022FY2023: Operating cash flow −$6.0MFY2023: Net borrowing −$597KFY2023: Capital spending −$23KFY2023: Acquisitions −$2.2MFY2023FY2024: Operating cash flow −$7.3MFY2024: Net borrowing $23KFY2024: Shares issued $5.7MFY2024: Capital spending −$79K$5.7MFY2024FY2025: Operating cash flow −$9.3MFY2025: Net borrowing −$370KFY2025: Shares issued $12.1MFY2025: Capital spending −$61K$12.1MFY2025
Over these 5 years operating cash flow totalled −$28.8M; the largest uses were operating cash flow ($28.8M) and acquisitions ($2.2M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$2.6M
Debt$160K
Net cash$2.4M
Cash runway2 months

bioAffinity Technologies is burning cash: its operations consume cash, a free cash flow of −$13.0M a year at the current rate against $2.6M of cash and investments: a runway of about 2 months before any new financing.

Where the cash came from and went

bioAffinity Technologies: sources (+) and uses (−) of cash, Q3 2026bioAffinity Technologies: sources (+) and uses (−) of cash, Q3 2026Other financing$4.1MOperating cash flow−$3.9MCash drawn (+) / kept (−)−$120KCapital spending−$77KNet borrowing (+) / repaid (−)−$20K
bioAffinity Technologies: sources (+) and uses (−) of cash, TTM to Q3 2026bioAffinity Technologies: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow−$12.9MShares issued$9.0MCash drawn (+) / kept (−)$5.1MOther financing−$895KNet borrowing (+) / repaid (−)−$191KCapital spending−$173K

From profit to cash

bioAffinity Technologies: net income to operating cash flow, Q3 2026bioAffinity Technologies: net income to operating cash flow, Q3 2026Net income−$5.3MDepreciation & amortization$67KStock-based pay$139KReceivables$153KInventory−$26KPayables−$21KAccrued liabilities−$271KDeferred revenue$18KPrepaid and other assets$31KOperating cash flow−$3.9M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$3.9M−$77K−$20K—−$120K−$3.9M
Q2 2026−$3.2M−$90K−$66K—$669K−$3.3M
Q1 2026−$3.2M−$6K−$119K—$3.4M−$3.2M
Q4 2025−$2.6M−$1−$73K—$1.2M−$2.6M
Q3 2025−$2.5M$4K$43K$6.5M−$6.9M−$2.5M
Q2 2025−$2.6M−$13K−$167K—−$358K−$2.7M
Q1 2025−$1.6M−$51K−$139K—$661K−$1.7M
Q4 2024−$1.7M−$1−$188K$2.7M−$349K−$1.7M

bioAffinity Technologies: income statement and cash flow

bioAffinity Technologies, Q3 2026: revenue $1.1M (-26% year over year), operating margin -328.0%. The chart follows the revenue to costs, profit and cash.

bioAffinity Technologies: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.